Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo
IRIS, D3466C00001
Phase 3 small_molecule active
Quick answer
Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo for Active Proliferative Lupus Nephritis is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Active Proliferative Lupus Nephritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active